NuView Life Sciences’ leading technology, NV-VPAC1TM consists of a series of peptide analogs that target the vasoactive intestinal peptide receptor type 1 (VPAC1).

The VPAC1 receptor becomes overexpressed in certain key malignancies including breast, prostate, colon, bladder, and endometrial cancer. Attaching a molecular imaging or therapeutic component to a NV-VPAC1(tm) peptide enables NuView Life Sciences to develop a series of precisely targeted products that may be used in the diagnosis and treatment of cancer.

NV-VPAC1TM-PET in Breast Cancer

NuView Life Sciences is currently developing the NV-VPAC1 technology as a Positron Emission Tomography (PET) imaging agent for the in vivo diagnosis of breast and prostate cancer by combining an NV-VPAC1 peptide with a medical imaging isotope.

NV-VPAC1TM-PET in Breast Cancer

The primary imaging modality used in breast cancer screening is mammography and every year, women undergo 40 million mammograms in the United States alone. During screening, if a woman has an abnormal mammographic finding, additional imaging and a biopsy may be recommended. Approximately 1.7 million breast biopsies are performed every year as a result of the observation of suspicious lesions. Approximately 1.3 million of these biopsies result in a benign diagnosis (approximately 80%). The estimated annual cost of negative biopsies in the U.S. is approximately $4B.

Since the VPAC1 receptor is highly expressed on breast cancer cells with minimal expression on nonmalignant tissues, the utilization of NV-VPAC1 technology to improve the specificity of the early stage diagnosis of breast cancer has the potential to significantly reduce the number of negative breast biopsies that are done annually as part of the breast cancer screening process. NuView Life Sciences estimates that from 20% to 50% of women who are scheduled for a breast biopsy may have the option to undergo a NV-VPAC1TM-PET scan to improve the image-based diagnosis of breast cancer and avoid the necessity of a breast biopsy.

For example, the NV-VPAC1-PET technology can potentially be used in patients who have had a mammogram with suspicious findings and in whom a breast biopsy is indicated. Such patients could undergo an NV-VPAC1TM-PET scan post-mammography and prior to the biopsy. NuView Life Sciences is in the process of designing clinical trials to demonstrate the benefit of the NV-VPAC1TM-PET technology in this setting.

In the United States, breast cancer is the most common cancer among women of all races and ethnicities. An estimated 249,260 new cases of breast cancer with 40,890 deaths are forecasted in 2016. Approximately 12.3% of women will be diagnosed with breast cancer at some point in their lifetime.